Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B

Table 6

Comparison of clinical characteristics of ETV-resistant hepatitis B patients between NA-naïve patients and patients with prior NA exposure.

Characteristics	NA naive patients (n = 12)	Patients with prior NA exposure (n = 3)	value
Age at the beginning (years)	51.3 ± 12.6	40.7 ± 9.0	n. s.
Gender (M/F (n, %))	9 (75)/3 (25)	3 (100)/0 (0)	n. s.
Baseline AST (U/L)	64.1 ± 29.2	84.0 ± 87.0	n. s.
Baseline ALT (U/L)	103.9 ± 57.5	214.7 ± 266.9	n. s.
Baseline HBV DNA (LogC/mL)	7.8 ± 1.4	4.1 ± 1.0
Baseline HBeAg (+/− (n, %))	8 (66.6)/4 (33.3)	2 (66.6)/1 (33.3)	n. s.
Baseline HBcrAg (Log U/mL)	6.5 ± 0.8	4.9 ± 1.4
Genotype (B/C (n, %))	3 (25.0)/9 (75.0)	0 (0.0)/3 (100.0)	n. s.
HCC (n, %)	2 (16.7)	0 (0)	n. s.
Fibrosis stage (F1/F2/F3/F4/unknown (n, %))	2 (16.7)/6 (50.0)/0 (0.0)/1 (8.3)/3 (25.0)	1 (33.3)/1 (33.3)/1 (33.3)/0 (0.0)/0 (0.0)	n. s.
Period to next treatment (months)	75.6 ± 36.0	62.3 ± 41.5	n. s.
Genotypic resistance (after ETV) (detected/undetectable/no sample (n, %))	1 (8.3)/10 (83.3)/1 (8.3)	0 (0.0)/3 (100.0)/0 (0.0)	n. s.